ERBB2 and neoplasm: Chemotherapy is the backbone of treatment for both early-stage and metastatic TNBC because this tumor lacks hormone receptors and Her2 amplification, making endocrine therapy or Her2-directed therapy inefficient as targeted therapy [3]. Chemotherapy also lowers the risk of recurrence and death and is now frequently advised as preoperative (neoadjuvant) therapy [3].